Terapia intraperitoneal paliativa en ascitis maligna refractaria


  • Mauricio Antonio Castaño Cárcamo Instituto Nacional de Cancerología
  • Angélica Viviana Fletcher Prieto Instituto Nacional de Cancerología



Palabras clave:

Ascitis, Neoplasias, Infusiones parenterales, Infusiones intra-abdominales, Terapia intraperitoneal, Cuidados paliativos, Supervivencia, Calidad de vida


El tratamiento convencional de la ascitis maligna refractaria es un reto oncológico pues provee mejoría sintomática poco duradera. La terapia intraperitoneal ha sido evaluada principalmente en reportes y series de casos, y en algunos ensayos clínicos, estudiados principalmente en la ascitis por cáncer ovárico y gastrointestinal. Esta terapia incluye: isótopos radioactivos, quimioterapia con hipertermia y sin esta, terapia inmunológica, biológica y otras. Los tratamientos más exitosos con respuestas variables, y aunque la comparación directa no es posible, son: la quimioterapia intraperitoneal hipertérmica (respuesta global entre 85,7% y 100%) y el catumaxomab, que frente a la paracentesis demostró una supervivencia libre de punción de 46 vs 11 días (HR 0,254) y una mediana a la próxima paracentesis de 77 vs 13 días (HR 0,169), con impacto positivo en la calidad de vida, principal fin en el escenario paliativo. La investigación en este campo continúa buscando resultados más duraderos, seguros y costo-efectivos.

Biografía del autor/a

Mauricio Antonio Castaño Cárcamo, Instituto Nacional de Cancerología

Departamento de Dolor y Cuidado Paliativo, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Angélica Viviana Fletcher Prieto, Instituto Nacional de Cancerología

Departamento de Ginecología Oncología, Instituto Nacional de Cancerología, Bogotá D. C., Colombia

Referencias bibliográficas

Sangisetty SL, Miner TJ. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87-95.


Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8:1104-9.


Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198:999-011.


Chung M, Kozuch P. Treatment of malignant ascites. Curr Treat Options Oncol. 2008;9(2-3):215-33.


Wu Y, Pan M, Cui S, Ba M, Chen Z, Ruan Q. Efficacy and safety of ultrasound-guided continuous hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites: a midterm study of 36 patients. Onco Targets Ther. 2016;9:403-7.


Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79:144-53.


Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18:1-9.


Sibio S, Fouad Atta JM, Biacchi D, Naticchioni E, Cardi M. Palliative Treatments in Treatment of Peritoneal Surface Malignancies. Di Giorgio A, Pinto E, editors. Milano: Springer Milan; 2015. 349-360; chap 23 p.


Ammouri L, Prommer EE. Palliative treatment of malignant ascites: profile of catumaxomab. Biologics. 2010;4:103-10.


Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-63.


Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273-82.


Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55:1172-81.


Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 2009;29:3353-9.

Garofalo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32:682-5.


Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional antiEpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13:3899-905.


Bohn KA, Ray CE. Repeat Large-Volume Paracentesis Versus Tunneled Peritoneal Catheter Placement for Malignant Ascites: A Cost-Minimization Study. AJR Am J Roentgenol. 2015;205:1126-34.


Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 2009;14:1242-51.


Narayanan G, Pezeshkmehr A, Venkat S, Guerrero G, Barbery K. Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med. 2014;17:906-12.


Xue SL, Deng X, Liu Y, Su HF, Hu ML, Xie CY. Intraperitoneal recombinant human endostatin combined with chemotherapy for refractory malignant ascites due to gastrointestinal cancer: a pilot study. Hepatogastroenterology. 2013;60:118-23.


Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective Chart Review. J Pain Symptom Manage. 2009;38:341-9.


Saâda E, Follana P, Peyrade F, Mari V, Franc¸ois É. Physiopathologie et prise en charge des ascites malignes réfractaires. Bull Cancer. 2011;98:679-87.


Ostrowski MJ. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer. 1986;57:721-7.


Oh SY, Kwon H-C, Lee S, Lee DM, Yoo HS, Kim S-H, et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol. 2007;37:930-5.


Yonemori K, Okusaka T, Ueno H, Morizane C, Takesako Y, Ikeda M. FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. Hepatogastroenterology. 2007;54:2383-6.

Bonte FJ, Storaasli JP, Weisberger AS. Comparative evaluation of radioactive colloidal gold and nitrogen mustard in the treatment of serous effusions of neoplastic origin. Radiology. 1956;67:63-6.


Jackson GL, Blosser NM. Intracavitary chromic phosphate (32P) colloidal suspension therapy. Cancer. 1981;48:2596-8.


Ariel IM, Oropeza R, Pack GT. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer. 1966;19:1096-102.


Walter J. Radioactive gold in malignant effusions. Proc R Soc Med. 1953;46:466-71.


Dybicki J. Treatment of Pleural and Peritoneal Effusion with Intracavitary Colloidal Radiogold (Au 198). Arch Intern Med. American Medical Association. 1959;104:802.


Hahn PF, Meneely GR, Carothers EL. The use of gold and silvercoated radioactive gold colloids in the palliation of ascites and pleural effusions. Br J Radiol. The British Institute of Radiology. 1958;31:240-5.


Vergote IB, Winderen M, De Vos LN, Tropé CG. Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy. Cancer. 1993;71:2250-60.


Taylor A, Baily NA, Halpern SE, Ashburn WL. Loculation as a contraindication intracavitary 32P-chromic phosphate therapy. J Nucl Med. 1975;16:318-9.

Andersen AP, Brincker H. Intracavitary thiotepa in malignant pleural and peritoneal effusions. Acta Radiol Ther Phys Biol. 1968;7:369-78.


Clarke TH. Radioactive colloidal gold AU198 in the treatment of neoplastic effusions. Q Bull Northwest Univ Med Sch. 1952;26:98-104.

Walton RJ. The palliative treatment of malignant pleural and peritoneal effusions with radio-active colloidal gold. J Fac Radiol. 1952;4:130-3.


Andrews GA, Root SW, Kerman HD, Bigelow RR. Intracavitary colloidal radiogold in the treatment of effusions caused by malignant neoplasms. Ann Surg. 1953;137:375-81.


Storaasli JP, Bonte FJ, King DP, Friedell HL. The use of radioactive colloidal gold in the treatment of serous effusions of neoplastic origin. Surg Gynecol Obstet. 1953;96: 707-10.

Seaman WB. Radioactive gold in the treatment of malignant effusions. JAMA J Am Med Assoc. American Medical Association;. 1953;153:630.


Kent EM, Moses C, Ford WB, Kutz ER, George RS. Radioactive isotopes in management of carcinomatosis of serous body cavities. AMA Arch Intern Med. 1954;94:334-40.


Moses C, Kent E, Boatman JB. Experimental and clinical studies with radioactive colloidal gold in the therapy of serous effusions arising from cancer. Cancer. 1955;8:417-23.


Simon N. Radioactive gold treatment: results in 85 effusions due to cancer. J Mt Sinai Hosp N Y. 1955;22:96-8.

Russo PE, Coin CG, Evans WW. Use of radioactive gold in pleural effusion and ascites. J Okla State Med Assoc. 1955;48:369-71.

Kligerman MM, Habif DV. The use of radioactive gold in the treatment of effusion due to carcinomatosis of the pleura and peritoneum. Am J Roentgenol Radium Ther Nucl Med. 1955;74:651-6.

Kepp RK, Hartl H, Muller K. The value of radio-gold 198 in gynecological radiotherapy. Dtsch Med Wochenschr. 1955;80:19-21.


Brennan MJ, Mcginnis KD, Preuss L. Experience with intracavitary radio-gold at Henry Ford Hospital. Henry Ford Hosp Med Bull. 1956;4:89-93.

Copeland BE, Osborne MP. Intracavitary administration of radioactive colloidal gold (Au 198) for the treatment of malignant effusions; a report of thirty-one cases and an appraisal of results. N Engl J Med. 1956;255:1122-8.


Millar O, Macdonald JC. Radioactive gold in malignant effusions. Can Med Assoc J. 1956;74:783-8.

Ireton RJ, Ullery JC. The management of ascites with radioactive gold. Surg Gynecol Obstet. 1956;103:437-42.

Chang CH, Janzen AH, Skorneck AB, Rosenbaum PJ. Treatment of malignant effusions by intracavitary injection of radioactive colloidal gold. Am J Roentgenol Radium Ther Nucl Med. 1957;77:486-92.

Hofmann-Credner D. En: Domanig E, editor. Bisherige Ergebnisse der Krebsbehandlung mit Radiogold in Zehnte Österreichische Ärztetagung Wien. Vienna: Springer Vienna; 1957. p. 188-202.


Karras BG, Moss WT. Radioactive gold in the control of malignant serous effusions. Q Bull Northwest Univ Med Sch. 1962;36:57-9.

Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol. 2015;21:10936-47.


Hager ED, Dziambor H, Höhmann D, Mühe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer. 2001;11 Suppl 1:57-63.


Appelqvist P, Silvo J, Salmela L, Kostiainen S. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol. 1982;20:238-42.


Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990;8:2054-61.


Maiche AG. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Anticancer Drugs. 1994;5:305-8.


Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547-50.


Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology. 2010;78:40-6.


Koda K, Nakazawa O, Terada S, Kure T, Morita K, Hirayama M, et al. Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics. Gan No Rinsho. 1988;34:191-5.

Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. American Medical Association. 1955;159:1704-7.


Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976;38:1903-8.


Lind SE, Cashavelly B, Fuller AF. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary. Surg Gynecol Obstet. 1988;166:519-22.

Hagiwara A, Takahashi T, Sawai K, Sakakura C, Tsujimoto H, Osaki K, et al. Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites-a pilot study. Anticancer Drug Des. 1993;8:463-70.

Lorusso V, Catino A, Gargano G, Fioretto A, Berardi F, de Lena M. Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. Eur J Gynaecol Oncol. 1994;15:75-80.

Link KH, Hepp G, Staib L, Butzer U, Böhm W, Beger HG. Intraperitoneal regional chemotherapy with mitroxantrone. Cancer Treat Res. 1996;81:31-40.


Link KH, Roitman M, Holtappels M, Runnebaum I, Urbanzyk H, Leder G, et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am. 2003;12:865-72, xvi-xvii.


Huang X-E, Wei G-L, Huo J-G, Wang X-N, Lu Y-Y, Wu X-Y, et al. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev. 2013;14:2611-4.


Tsubamoto H, Takeuchi S, Ito K, Miyagi Y, Toyoda S, Inoue K, et al. Feasibility and efficacy of intraperitoneal docetaxel administration as salvage chemotherapy for malignant gynaecological ascites. J Obstet Gynaecol. 2015;35:69-73.


Mura G, Federici O, Garofalo A. Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer: Indications and Technical Notes in Surgery in the Multimodal Management of Gastric Cancer. de Manzoni G, Roviello F, Siquini W, editors. Milano: Springer Milan; 2012. 107-112.


Gilly FN, Carry PY, Brachet A, Sayag AC, Panteix G, Salle B, et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacother. 1992;9:177-81.

Benoit L, Cheynel N, Ortega-Deballon P, Giacomo G Di, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15:542-6.


Cui S, Ba M, Tang Y, Liu J, Wu Y, Wang B, et al. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncol Rep. 2012;28:1325-31.


Ba MC, Long H, Cui SZ, Tang YQ, Wu YB, Zhang XL, et al. Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites. Surg Endosc. 2013;27:2735-43.


Kusano H, Miyashita K, Matsuo T, Jibiki M, Nakagoe T, Miura T, et al. Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination. Gan To Kagaku Ryoho. 1993;20:1622-5.

Franc¸ois Y, Grandclément E, Sayag-Beaujard AC, Glehen O, Sadeghi-Looyeh B, Bienvenu J, et al. Intraperitoneal chemohyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis. J Chir (Paris). 1997;134(5-6):237-42.

Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, et al. Laparoscopic continuous hyperthermic peritoneal perfusion. J Am Coll Surg. 2001;193:225-9.


Ba MC, Cui SZ, Lin SQ, Tang YQ, Wu YB, Wang B, et al. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16:1901-7.


Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multiinstitutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100:331-4.


Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15:339-44.


De Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouché O. Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites? Case Rep Gastroenterol. 2012;6:166-70.


Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gullà N, et al. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 2008;18:426-8.


Facchiano E, Scaringi S, Kianmanesh R, Sabate JM, Castel B, Flamant Y, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2008;34:154-8.


Graziosi L, Bugiantella W, Cavazzoni E, Donini A. Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report. G Chir. 2009;30:237-9 [citado el 18 de febrero de 2016].

Van den Houten MML, van Oudheusden TR, Luyer MDP, Nienhuijs SW, de Hingh IHJT. Respiratory distress due to malignant ascites palliated by hyperthermic intraperitoneal chemotherapy. World J Gastrointest Surg. 2015;7:39-42.


Valle SJ, Alzahrani NA, Alzahrani SE, Liauw W, Morris DL. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg. 2015;23 Pt A:176-80.


Ba MC, Long H, Zhang XL, Gong YF, Tang YQ, Wu YB, et al. Laparoscopic Hyperthermic Intraperitoneal Perfusion Chemotherapy for Patients with Malignant Ascites Secondary to Unresectable Gastric Cancer. J Laparoendosc Adv Surg Tech A. 2016;26:32-9.


Lu C, Li L, Luo Z, Cui Y, Fu P, Zhou J, et al. Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites. Neoplasma. 2016;63.


Ba MC, Long H, Cui SZ, Tang YQ, Wu YB, Zhang XL, et al. Erratum to: Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites. Surg Endosc. 2014;28:1401-1401.


Rambaldi A, Introna M, Colotta F, Landolfo S, Colombo N, Mangioni C, et al. Intraperitoneal administration of interferon beta in ovarian cancer patients. Cancer. 1985;56:294-301.


Bezwoda WR, Seymour L, Dansey R. Intraperitoneal recombinant interferon-alpha 2 b for recurrent malignant ascites due to ovarian cancer. Cancer. 1989;64:1029-33.


Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer. 1993;71:2027-30.


Gebbia N, Mannino R, Di Dino A, Maxhouni L, Bellone N, Cinque L, et al. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. Anticancer Res. 1994;14(2B):739-45.

Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology. 2001;61:192-6.


Hirte HW, Miller D, Tonkin K, Findlay B, Capstick V, Murphy J, et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol. 1997;64:80-7.


Räth U, Kaufmann M, Schmid H, Hofmann J, Wiedenmann B, Kist A, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer. 1991;27:121-5.


Räth U, Schmid H, Karck U. Phase II trial of recombinant human tumor necrosis factor in patients with malignant ascites from ovarian carcinomas and non-ovarian tumors with intraperitoneal spread. Proc Am Soc Clin Oncol. 1991;10:187 (abstract).

Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res. 2006;26(5B):3701-7.

Currie JL, Gall S, Weed JC, Creasman WT. Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol. 1983;16:6-14.


Webb HE, Oaten SW, Pike CP. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum. Br Med J. 1978;1:338-40.


Katano M, Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery. 1983;93:365-73.

Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery. Elsevier. 1983;93:357-64.

Yamaguchi Y, Miyahara E, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, et al. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes. Br J Cancer. 2003;89:1876-84.


Wang Z, Zhuang R, Chen Y, Feng Y, Li Q, Liu T. A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:28-31.

Ai YQ, Cai K, Hu JH, Jiang LW, Gao YR, Zhao H, et al. The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med. 2014;7:4272-81.

Kaufmann M, Schmid H, Raeth U, Grischke EM, Kempeni J, Schlick E, et al. Therapy of ascites with tumor necrosis factor in ovarian cancer. Geburtshilfe Frauenheilkd. 1990;50:678-82.


Yamaguchi Y, Satoh Y, Miyahara E, Noma K, Funakoshi M, Takashima I, et al. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res. Jan;15(5 B):2201-6.

Ströhlein MA, Heiss MM. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol. 2010;6:1387-94.


Buckman R, de Angelis C, Shaw P, Covens A, Osborne R, KerrI, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol. Elsevier. 1992;47: 102-9.


Ward B, Mather S, Shepherd J, Crowther M, Hawkins L, Britton K, et al. The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. Br J Cancer. 1988;58:658-62.


Marmé A, Strauss G, Bastert G, Grischke E-M, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer. 2002;101:183-9.


Crysandt M, Neumann B, Das M, Engelbertz V, Bendel M, Galm O, et al. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol. 2007;79:546-9.


Ng T, Pagliuca A, Mufti GJ. Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Ann Hematol. 2002;81:405-6.


Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998;58:2594-600.

El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. ASCO Meet Abstr. 2007;25 18 suppl:9043.

Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol. 2008;111:527-9.


Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol.2006;102:425-8.


Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111:530-2.


Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs. 2010;28:887-94.


Sjoquist KM, Friedlander M, Mileshkin LR, Quinn M, Goh JC, Shannon CM, et al. The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer. ASCO Meet Abstr. 2014;32 15 suppl:TPS5627.


Eastern Regional Medical Center. Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable MalignantAscites [Internet]. Clinical Trials NCT02496286. 2015 [consultado el 1 de julio de 2015]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02496286?term=bevacizumab&cond=ascites&rank=4

DuNan CPGH. Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy [Internet]. Clinical Trials NCT01838538. [consultado el 19 de abril de 2013]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01838538?term=bevacizumab&cond=ascites&rank=5

Shen Lin PU. Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites [Internet]. Clinical Trials NCT01852409. [citado el 8 de mayo de 2013]. Disponibleen: https://clinicaltrials.gov/ct2/show/NCT01852409?term=bevacizumab&cond=ascites&rank=2

AIO-Studien-gGmbH. Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers [Internet]. Clinical Trials NCT01200121. [consultado el 9 de octubre de 2010]. Disponible en: https://clinicaltrials.gov/ct2/show/study/NCT01200121?term=bevacizumab&cond=ascites&rank=3

Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005;117:435-43.


Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res. 2014;34:1553-61.

Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209-21.


Belau A, Pfisterer J, Wimberger P, Kurzeder C, Du Bois A, Sehouli J, et al. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer. ASCO Meet Abstr. 2007;25 18 suppl:5556.

Stroehlein MA, Gruetzner KU, Tarabichi A, Jauch KW, Bartelheim K, Lindhofer H, et al. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis. ASCO Meet Abstr. 2006;24 18 suppl.

Parsons SL, Kutarska E, Koralewski P, Gore M, Wimberger P, Burges A, et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. ASCO Meet Abstr. 2007;25 18 suppl:5520.

Parsons S, Kutarska E, Koralewski P, Gore M, Wimberger P, Burges A. Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: results of a phase II/III study. Eur J Cancer. 2007;Suppl 5(4):311.


Parsons S, Murawa P, Kolesnik O, Ivanchenko V, Koralewski P, Razbadauskas A. Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study. Gastrointest-CanSympos. 2008, abstr. 106.

Fareed K, Parsons S, Koralewski P, Kutarska E, Stroehlein M, Gore M. Intraperitoneal treatment of malignant ascites due to epithelial tumors using the trifunctional antibody catumaxomab: results of a phase II/III study. 19th-Int-CongAntiCan-Treat. 2008;292.

Parsons S, Murawa P, Koralewski P, Kutarska E, Kolesnik O, Stroehlein M. Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: a phase II/III study. 4th-Ann-Meet-Am-Soc-Clin-Oncol. 2008;abstr. 3000.


Parsons S, Kutarska E, Koralewski P, Gore M, Wimberger P, Burges A. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study. J Clin Oncol. 2007;25 Suppl 18, abstr 5520.

Heiss M, Linke R, Friccius-Quecke H, Klein A, Hennig M, Lindhofer H. Catumaxomab treatment in gastric cancer patients with malignant ascites - subgroup-analysis of a pivotal trial. 15th-ECCO-34th-ESMO-2009. 2009;abstr. PD-6507.


Gonschior A, Gilet H, Heiss M, Hennig M, Moehler M, Schmalfeldt B. Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone. Eur Mentor Coach Counc. 2011, abstr. 3004.


Wimberger P, Gilet H, Gonschior A-K, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23:1979-85.


Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, et al. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014;24:1583-9.


Cella D, Neubauer N, Thomas J, Kutner J, Seiden MV. The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecol Oncol. 2013;128:187-90.


Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, et al. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol. 2014;31:76.


Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012;130:2195-203.


Seeber A, Braicu I, Untergasser G, Nassir M, Fong D, Botta L, et al. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. Oncotarget. 2015;6:25017-23.


Pietzner K, Linke R, Jäger M, Lindhofer H, Friccius-Quecke H, Chen F, et al. Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). J Clin Oncol. 2010;28(15s), abstr TPS155.


Pietzner K, Jäger M, Schoberth A, Oskay-Özcelik G, Kuhberg M, Lindhofer H, et al. First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med Oncol. 2012;29:1391-6.


Pietzner K, Vergote I, Santoro A, Chekerov R, Marmé F, Rosenberg P, et al. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study. Med Oncol. 2014;31:308.


Pietzner K, Vergote I, Santoro A, Marme F, Rosenberg P, Friccius-Quecke H, et al. Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS). J Clin Oncol - 2013 ASCO Annu Meet. 2013;31:suppl; abstr 5582.


Thomaidis T, Wörns MA, Galle PR, Möhler M, Schattenberg JM. Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma-a report of 2 cases. Oncol Res Treat. 2014;37:674-7.


Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73:449-56.


Krawczyk M, Zimmermann S, Vidacek D, Lammert F. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report. Onkologie. 2012;35:592-4.


Zhao J, Chen X, Zhang A, Xu F, Hu M, Xie C, et al. A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer. Med Oncol. 2014;31:930.


Mäenpää J, Kivinen S, Räisänen I, Sipilä P, Väyrynen M, Gröhn P. Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. Ann Chir Gynaecol Suppl. 1994;208:25-7.

Jia W, Zhu Z, Zhang T, Fan G, Fan P, Liu Y, et al. Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. Cancer Chemother Pharmacol. 2013;71:1585-90.


Zhao H, Li X, Chen D, Cai J, Fu Y, Kang H, et al. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Med Oncol. 2015;32:292.


Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol. 1997;23:526-31.


Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res. 1998;4:1899-902.

Mackey JR, Wood L, Nabholtz J-M, Jensen J, Venner P. A Phase II Trial of Triamcinolone Hexacetanide for Symptomatic Recurrent Malignant Ascites. J Pain Symptom Manage. 2000;19:193-9.


Jenkin RP, Bamford R, Patel V, Kelly L, Stern S. The use of intraperitoneal triamcinolone acetonide for the management of recurrent malignant ascites in a patient with non-Hodgkin's lymphoma. J Pain Symptom Manage. 2008;36:e4-5.


Shoji T, Takatori E, Miura Y, Takada A, Omi H, Kagabu M, et al. Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer. Int J Gynecol Cancer. 2014;24: 1093-7.


Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res. 2006;12:2517-25.


Tochner Z, Mitchell JB, Smith P, Harrington F, Glatstein E, Russo D, et al. Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer. 1986;53:733-6.


Cómo citar

Castaño Cárcamo, M.A. y Fletcher Prieto, A.V. 2018. Terapia intraperitoneal paliativa en ascitis maligna refractaria. Revista Colombiana de Cancerología. 22, 1 (mar. 2018), 18–38. DOI:https://doi.org/10.35509/01239015.171.


Los datos de descargas todavía no están disponibles.






Artículos de revisión
Crossref Cited-by logo